In this study, we aimed to determine if simultaneous inhibition of BCR-ABL1 oncogenic tyrosine kinase and PAK1/2 serine/threonine kinase exert better anti-CML effect than that of individual treatments. The gene discussed is PAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.